`The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1

被引:0
|
作者
Horakova, Magda [1 ,2 ]
Horak, Tomas [1 ,2 ]
Bednarik, Josef [1 ,2 ]
Vohanka, Stanislav [1 ,2 ]
机构
[1] Univ Hosp Brno, ERN EURO NMD Ctr, Dept Neurol, Brno, Czech Republic
[2] Masaryk Univ, Fac Med, Brno, Czech Republic
关键词
Myotonia; Myotonic dystrophy; Methylprednisolone; Corticosteroids; Muscle relaxation; Therapy; CHANNEL;
D O I
10.1016/j.nmd.2020.03.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia. Myotonia severity was expressed as relaxation time after voluntary contraction and as a patient-reported outcome using the Czech version of the Myotonia Behavior Scale. The patient was being treated for a flare of ulcerative colitis, starting with 32 mg of methylprednisolone and reducing the dose by 4 mg a week. The symptoms of myotonia began to wear off three weeks after starting methylprednisolone and had totally disappeared by four weeks after starting methylprednisolone. The first symptoms of myotonia returned about a month after the last dose of methylprednisolone and reached a peak of severity more than two months after the final dose. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 50 条
  • [1] Grip and Percussion Myotonia in Myotonic Dystrophy Type 1
    Hughes, Brian N.
    Hogue, Jacob S.
    Hsieh, David T.
    JOURNAL OF PEDIATRICS, 2014, 164 (05): : 1234 - +
  • [2] Toe-extension myotonia in myotonic dystrophy type 1
    Mankodi, Ami
    Grunseich, Christopher
    NEUROLOGY, 2015, 85 (02) : 203 - 203
  • [3] Cardiovascular effects of mexiletine for treatment of myotonia in myotonic dystrophy type 1
    Salguero-Bodes, Rafael
    Ruiz-Curiel, Anibal
    Palomino-Doza, Julian
    Valverde-Gomez, Maria
    Dominguez-Gonzalez, Cristina
    Arribas-Ynsaurriaga, Fernando
    REVISTA ESPANOLA DE CARDIOLOGIA, 2021, 74 (11): : 986 - 987
  • [4] Dehydroepiandrosterone sulfate (DHEAS) therapy for myotonic dystrophy type 1 and myotonia
    Sugino, M
    INTERNAL MEDICINE, 2005, 44 (12) : 1213 - 1214
  • [5] Myotonic dystrophy type 2 with calf hypertrophy and no myotonia
    Milone, M.
    JOURNAL OF NEUROLOGY, 2006, 253 : 105 - 105
  • [6] Investigation of Ranolazine as an Anti-myotonia Treatment in Myotonic Dystrophy Type 1
    Lawless, Michael
    Arnold, William
    Agriesti, Julie
    Moravec, Trevor
    NEUROLOGY, 2018, 90
  • [7] A patient with myotonic dystrophy type 1 and parkinsonism
    Choi, J.
    Lee, J.
    Kim, H.
    Jeon, B.
    MOVEMENT DISORDERS, 2018, 33 : S803 - S804
  • [8] There is no correlation between muscle strength and myotonia in patients with myotonic dystrophy type 1
    Preisler, N.
    Cathrine, Orngreen M.
    Andersen, G.
    Dysgaard, Jeppesen T.
    Colding-Jorgensen, E.
    Clausen, T.
    Schwartz, M.
    Duno, M.
    Vissing, J.
    NEUROMUSCULAR DISORDERS, 2007, 17 (9-10) : 855 - 856
  • [9] A patient with neurofibromatosis type 1 and myotonic dystrophy type 1
    Esra, Serdaroglu
    Ceren, Gunbey
    Banu, Anlar
    NEUROLOGY ASIA, 2022, 27 (02) : 503 - 506
  • [10] Unexpected resistance to pancuronium in a patient with myotonic dystrophy (myotonia dystrophica)
    Kodama K.
    Akata T.
    Sasaki T.
    Sakaguchi Y.
    Takahashi S.
    Journal of Anesthesia, 2000, 14 (3) : 160 - 163